Cerevance Media Center

Current News

May 2, 2024

Cerevance Achieves First Milestone in Research Collaboration with Merck

Cerevance achieves first milestone in research collaboration with Merck, known as MSD outside of the United States and Canada. The research collaboration, which was announced in August of 2022, focuses on the identification of novel therapeutic targets for Alzheimer’s disease. The achievement of this milestone triggers an undisclosed payment from Merck to Cerevance.

READ FULL

April 25, 2024

Cerevance Adds $47 Million in Series B-1 Extension to Advance Robust Clinical Pipeline

Cerevance announced an initial closing of its Series B-1 Extension financing round that will add $47 million to the $51 million previously raised bringing the total Series B-1 raise to $98 million.

READ FULL

April 22, 2024

Cerevance Publishes CVN293 in ACS Medicinal Chemistry Letters

Cerevance announces that the peer-reviewed journal, ACS Medicinal Chemistry Letters, has published the manuscript titled “Discovery of CVN293, a Brain Permeable KCNK13 (THIK-1) Inhibitor Suitable for Clinical Assessment”.

READ FULL

February 15, 2024

Cerevance Announces Publication of CVN766 in Bioorganic & Medicinal Chemistry Letters

Cerevance Announces Publication of CVN766 in Bioorganic & Medicinal Chemistry Letters describing the discovery and initial development of CVN766 in the peer-reviewed journal, Bioorganic & Medicinal Chemistry Letters. In the publication titled, “Discovery and first-time disclosure of CVN766, an exquisitely selective orexin 1 receptor antagonist”

READ FULL

News Archive

Thank you! Your submission has been received!
Oops! Something went wrong while submitting the form.
No items found.

May 20, 2024

Cerevance to Participate in Precision Neurotherapeutics Panel During the 2024 BIO International Convention

Date:
Tuesday, June 4, 2024
Time:
11 am – 12 pm, PT
Location:
San Diego, CA
Media:
Panel Discussion
Read full

May 9, 2024

Cerevance Presents at IAPRD XXIX World Congress on Parkinson’s Disease and Related Disorders

Date:
Monday, May 20, 2024
Time:
9:35 – 10:20am
Location:
Lisbon, Portugal
Media:
Oral Presentation
Read full

April 29, 2024

Cerevance to Participate at Wells Fargo Virtual Private Biotech Symposium

Date:
Monday, May 6, 2024
Time:
Per meeting scheduling
Location:
Virtual
Media:
Scheduled Meetings
Read full

Events Archive

Thank you! Your submission has been received!
Oops! Something went wrong while submitting the form.
No items found.

May 30, 2023

A Phase 1, Randomized, Double-Blind, Placebo-Controlled, Safety, Tolerability, & W9 Pharmacokinetic Study of Escalating Single & Multiple Doses of CVN766, an OX1R Highly Selective Antagonist, in Healthy Subjects

Vitolo, O.

Viewview

May 9, 2023

Uncovering Novel Cell Types and Therapeutic Targets in Alzheimer's Disease Using Cerevance’s NETSseq Platform and Analysis

Stirparo, G., Xu, X., Lizio, M., Powell, J., Cheung, T., Bayraktar, G., Christie, L., Roberts, M., Crane, G., Cadwalladr, D., Lawrence, J., Sheardown, S., Ossola, B., Brice, N.L., Page, K., Dawson, L.A., Carlton, M.B.

Viewview

May 2, 2023

Phase 1 Study of CVN424, a Novel GPR6 Inverse Agonist

Margolin, D.H., Brice, N.L., Davidson, A.M., Matthews, K.L., Carlton, M.B.

Viewview

April 1, 2023

CVN424, a Novel GPR6 Inverse Agonist Demonstrates Efficacy in an Adjunctive Parkinson’s Disease Phase 2 Clinical Trial

Kieburtz, K., Margolin, D., Dubow, J., Matthews, K., Burli, R., Dawson, L.A., Ye, N., Carlton, M.B., Brice, N.L.

Viewview

March 31, 2023

NETSseq Reveals Deep Molecular Insights Into Alzheimer’s and Parkinson’s Disease and Facilitates Identification of Novel Therapeutic Targets

Xiao, X., Stirparo, G., Lizio, M., Powell, J., Cheung, T., Cadwalladr, D., Lawrence, J., Sheardown, S., Ossola, B., Brice, N.L., Page, K., Dawson, L.A., Carlton, M.B.

Viewview

March 1, 2023

NETSseq Provides Deep Molecular Insights into Alzheimer’s Disease Progression Enabling Selection of Novel Therapeutic Targets

Christie, L., Xu, X., Stirparo, G., Lizio, M., Powell, J., Dickson, L., Cheung, T., Cadwalladr, D., Lawrence, J., Sheardown, S., Ossola, B., Brice, N.L., Page, K., Dawson, L.A., Carlton, M.B.

Viewview